Molecular Aspects of Chemotherapy
暂无分享,去创建一个
[1] D. Helfman,et al. A homogeneous cyclic CMP phosphodiesterase hydrolyzes both pyrimidine and purine cyclic 2':3'- and 3':5'-nucleotides. , 1982, The Journal of biological chemistry.
[2] A Wlodawer,et al. Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases. , 1991, Biochemistry.
[3] Designing CD4 immunoadhesins for AIDS therapy. , 1990, Disease markers.
[4] D. Shugar. Progress with antiviral agents , 1974, FEBS letters.
[5] Thomas P. J. Garrett,et al. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains , 1990, Nature.
[6] F. Karst,et al. Ertosterol biosynthesis in Saccharomyces cerevisiae: mutants deficient in the early steps of the pathway. , 1977, Molecular & general genetics : MGG.
[7] J. Payne. Oligopeptide transport in Escherichia coli. Specificity with respect to side chain and distinction from dipeptide transport. , 1968, The Journal of biological chemistry.
[8] E. Borowski,et al. Substrate specificity of peptide permeases in Candida albicans , 1988 .
[9] T. Chou,et al. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine. , 1991, Molecular pharmacology.
[10] N. Brown,et al. Deoxyribonucleotide analogs as inhibitors and substrates of DNA polymerases. , 1990, Pharmacology & therapeutics.
[11] J. Dzik,et al. Interaction of the 5'-phosphates of the anti-HIV agents, 3'-azido-3'-deoxythymidine and 3'-azido-2',3'-dideoxyuridine, with thymidylate synthase. , 1988, Biochemical and biophysical research communications.
[12] L. Tomaszewski. [Peptide transport]. , 1976, Polski tygodnik lekarski.
[13] D. Montefiori,et al. Antibody-independent, complement-mediated enhancement of HIV-1 infection by mannosidase I and II inhibitors. , 1989, Antiviral research.
[14] C. Higgins,et al. Anaerobic and leucine-dependent expression of a peptide transport gene in Salmonella typhimurium , 1984, Journal of bacteriology.
[15] E. De Clercq,et al. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. , 1987, Antiviral research.
[16] D. R. Dubbs,et al. Characterization of nucleoside phosphotransferase and thymidine kinase activities of chick embryo cells and of chick-mouse somatic cell hybrids. , 1975, Archives of biochemistry and biophysics.
[17] I. H. Segel,et al. Adenosine 5'-phosphosulfate kinase from Penicillium chrysogenum. Purification and kinetic characterization. , 1984, The Journal of biological chemistry.
[18] T. Feizi,et al. Carbohydrate structures of glycoproteins and glycolipids as differentiation antigens, tumour-associated antigens and components of receptor systems , 1985 .
[19] D. Sandoli,et al. Structure-activity relationships of N2-substituted guanines as inhibitors of HSV1 and HSV2 thymidine kinases. , 1990, Journal of medicinal chemistry.
[20] C. Hassall,et al. Phosphonopeptides as Antibacterial Agents: Rationale, Chemistry, and Structure-Activity Relationships , 1979, Antimicrobial Agents and Chemotherapy.
[21] T. Traut,et al. Uridine kinase from Ehrlich ascites carcinoma. Purification and properties of homogeneous enzyme. , 1985, The Journal of biological chemistry.
[22] A. Webster. Cytomegalovirus as a possible cofactor in HIV disease progression. , 1991, Journal of acquired immune deficiency syndromes.
[23] J. D. Karkas,et al. Inhibition of human purine nucleoside phosphorylase by acyclic nucleosides and nucleotides. , 1987, Biochemical Pharmacology.
[24] R. Siliciano,et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation , 1988, Nature.
[25] A. Fridland,et al. Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells. , 1989, Molecular pharmacology.
[26] R. Lewis,et al. Phosphorylation of arabinosyl guanine by a mitochondrial enzyme of bovine liver. , 1989, Biochemical pharmacology.
[27] H. Mitsuya,et al. Molecular targets for AIDS therapy. , 1990, Science.
[28] D. Ives,et al. Properties of a highly purified mitochondrial deoxyguanosine kinase. , 1988, Archives of biochemistry and biophysics.
[29] E. De Clercq. Specific targets for antiviral drugs. , 1982, The Biochemical journal.
[30] E. De Clercq,et al. Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T‐cell lymphotropic virus (HTLV‐III)/lymphadenopathy‐associated virus (LAV) , 1986, International journal of cancer.
[31] G. F. Ames. Bacterial periplasmic transport systems: structure, mechanism, and evolution. , 1986, Annual review of biochemistry.
[32] A Wlodawer,et al. Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. , 1991, Biochemistry.
[33] C. Higgins,et al. Peptide transport in bacteria. , 1986, Methods in enzymology.
[34] Y. Satow,et al. Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A. , 1985, Journal of molecular biology.
[35] M. Navia,et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.
[36] W. Hendrickson. Stereochemically restrained refinement of macromolecular structures. , 1985, Methods in enzymology.
[37] R. Dewar,et al. Biosynthesis andProcessing ofHumanImmunodeficiency Virus Type1Envelope Glycoproteins: Effects ofMonensin on Glycosylation andTransport , 1989 .
[38] D. Sutton,et al. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture , 1987, Antimicrobial Agents and Chemotherapy.
[39] R. Wolfenden,et al. Inhibition of thymidine kinase by P1-(adenosine-5')-P5-(thymidine-5')-pentaphosphate. , 1986, The Journal of biological chemistry.
[40] J. Glorioso,et al. Demonstration and mapping of highly carbohydrate-dependent epitopes in the herpes simplex virus type 1-specified glycoprotein C. , 1987, The Journal of general virology.
[41] E. Borowski,et al. Synthesis and biological properties of N3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid dipeptides, a novel group of antimicrobial agents. , 1987, Journal of medicinal chemistry.
[42] R. L. Jarvest,et al. Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. , 1987, Journal of medicinal chemistry.
[43] F. Viola,et al. Synthesis and biological activity of azasqualenes, bis-azasqualenes and derivatives , 1987 .
[44] C. Miller,et al. Reversible repression and activation of measles virus infection in neural cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[45] John P. Overington,et al. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes , 1989, Nature.
[46] K. M. Hwang,et al. Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. , 1988, Science.
[47] S. Marsters,et al. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. , 1987, Science.
[48] E. De Clercq,et al. Inhibition of terminal N- and O-glycosylation specific for herpesvirus-infected cells: mechanism of an inhibitor of sugar nucleotide transport across Golgi membranes. , 1988, Virology.
[49] J. Gleaves,et al. The role of outer membrane proteins in peptide uptake by Escherichia coli , 1985 .
[50] M. R. Harnden. Development of 9-(4-hydroxy-3-(hydroxymethyl)but-1-yl)purines as potential therapeutic agents for treatment of human herpes virus infections , 1989 .
[51] R. Hanzlik,et al. [9] Synthesis of labeled squalene and squalene 2,3-oxide , 1969 .
[52] F. Viola,et al. Stereospecific synthesis of squalenoid epoxide vinyl ethers as inhibitors of 2,3-oxidosqualene cyclase , 1988 .
[53] C. Gilvarg,et al. Transport of impermeant substances in E. coli by way of oligopeptide permease. , 1973, Nature: New biology.
[54] R. Kunze,et al. Influence of sulfated carbohydrates on the accessibility of CD4 and other CD molecules on the cell surface and implications for human immunodeficiency virus infection , 1989, European journal of immunology.
[55] R. Freidinger,et al. Non-peptide ligands for peptide receptors. , 1989, Trends in pharmacological sciences.
[56] J. Groopman,et al. Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4 , 1989, Journal of virology.
[57] R. L. Jarvest,et al. An improved synthesis of the antiviral acyclonucleoside 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine , 1985 .
[58] J. D. Karkas,et al. Synthetic, Biochemical and Antiviral Aspects of Selected Acyclonucleosides and Their Derivatives. , 1986 .
[59] G. Richarme,et al. Study of binding protein-ligand interaction by ammonium sulfate-assisted adsorption on cellulose esters filters. , 1983, Biochimica et biophysica acta.
[60] J. Harb,et al. Purification of bovine liver cytosolic 5'-nucleotidase. Kinetic and structural studies as compared to the membrane isoenzyme. , 1988, European journal of biochemistry.
[61] E. Egyházi,et al. 5,6‐dichlororibofuranosylbenzimidazole (DRB) is phosphorylated in salivary gland cells of Chironomus tentans , 1979, FEBS letters.
[62] A. Sjoerdsma,et al. ANTI-HIV ACTIVITY OF CASTANOSPERMINE ANALOGUES , 1989, The Lancet.
[63] J. Payne,et al. Limitations to the use of radioactively labelled substrates for studying peptide transport in microorganisms , 1980, FEBS letters.
[64] S. Lederman,et al. Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV. , 1989, Journal of immunology.
[65] P. Reichard,et al. Cytoplasmic 5'(3')-nucleotidase from human placenta. , 1990, The Journal of biological chemistry.
[66] A. D. Broom. Rational design of enzyme inhibitors: multisubstrate analogue inhibitors. , 1989, Journal of medicinal chemistry.
[67] S. Ikeda,et al. Multisubstrate Analogs for Deoxynucleoside Kinases , 1985 .
[68] R. Miller,et al. Guanosine kinase from Trichomonas vaginalis. , 1991, Molecular and biochemical parasitology.
[69] E. De Clercq,et al. Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight. , 1991, Journal of medicinal chemistry.
[70] B. Walker,et al. Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and 3'-azido-3'-deoxythymidine , 1989, Antimicrobial Agents and Chemotherapy.
[71] S. Miller,et al. Cloning and characterization of the 2,3-oxidosqualene cyclase-coding gene of Candida albicans. , 1990, Gene.
[72] C. Higgins,et al. Uptake of cell wall peptides by Salmonella typhimurium and Escherichia coli , 1987, Journal of bacteriology.
[73] S. Olofsson,et al. Activity of herpes simplex virus type 1-specified glycoprotein C antigenic site II epitopes reversibly modulated by peripheral fucose or galactose units of glycoprotein oligosaccharides. , 1990, The Journal of general virology.
[74] S. Olofsson,et al. New Virus-Selective Inhibitor of Terminal Glycosylation Increasing Immunological Reactivity of a Viral Glycoprotein , 1990 .
[75] B. Walker,et al. Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[76] R Itoh,et al. Purification and some properties of cytosol 5'-nucleotidase from rat liver. , 1981, Biochimica et biophysica acta.
[77] D. Huso,et al. Sialic acids on the surface of caprine arthritis-encephalitis virus define the biological properties of the virus , 1988, Journal of virology.
[78] R. Axel,et al. soluble form of CD4 (T4) protein inhibits AIDS virus infection , 1988, Nature.
[79] E. Egyházi,et al. Kinetic analysis of uptake and phosphorylation of 5,6-dichlororibofuranosylbenzimidazole (DRB) by salivary gland cells of Chironomus tentans. , 1980, The Journal of biological chemistry.
[80] M. Greaves,et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.
[81] D. Sutton,et al. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir] , 1989, Antimicrobial Agents and Chemotherapy.
[82] I. Abe,et al. Purification and some properties of squalene-2,3-epoxide: lanosterol cyclase from rat liver. , 1991, Chemical and pharmaceutical bulletin.
[83] A Wlodawer,et al. X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[84] B. Walker,et al. HIV infection is blocked in vitro by recombinant soluble CD4 , 1988, Nature.
[85] D. Longo,et al. Death in the AIDS patient: role of cytomegalovirus. , 1983, The New England journal of medicine.
[86] The MHC-binding and gp120-binding functions of CD4 are separable. , 1990, Disease markers.
[87] F. Schuber,et al. Partial purification of 2,3-oxidosqualene-lanosterol cyclase from hog-liver. Evidence for a functional thiol residue. , 1988, Biochemical and biophysical research communications.
[88] D. Earnshaw,et al. Synthesis of isotopically chiral [13C]penciclovir (BRL 39123) and its use to determine the absolute configuration of penciclovir triphosphate formed in herpes virus infected cells , 1990 .
[89] S. Broder,et al. Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. , 1988, The Journal of biological chemistry.
[90] I. Pastan,et al. Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II-dependent functions. , 1990, AIDS research and human retroviruses.
[91] J. Payne. Peptides and micro-organisms. , 1976, Advances in microbial physiology.
[92] I. Weber,et al. Comparison of inhibitor binding in HIV‐1 protease and in non‐viral aspartic proteases: the role of the flap , 1990, FEBS letters.
[93] J. Morley,et al. Antibacterial activity and uptake into Escherichia coli of backbone-modified analogues of small peptides. , 1983, Journal of general microbiology.
[94] M. Jaskólski,et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.
[95] H. Varmus,et al. Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase , 1990, Journal of virology.
[96] P. Volberding,et al. Lack of response to suramin in patients with AIDS and AIDS-related complex. , 1987, The American journal of medicine.
[97] J. Weinstein,et al. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[98] S. Olofsson,et al. The antiherpes drug (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU) interferes with formation of N-linked and of O-linked oligosaccharides of the herpes simplex virus type 1 glycoprotein C. , 1985, Virology.
[99] W. Lüke,et al. Soluble CD4 molecules neutralize human immunodeficiency virus type 1 , 1988, Nature.
[100] E. Clercq. Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses , 1979 .
[101] L. Larsson,et al. A new class of synthetic antibacterials acting on lipopolysaccharide biosynthesis , 1987, Nature.
[102] M. Smith,et al. Simultaneous exploitation of different peptide permeases by combinations of synthetic peptide smugglins can lead to enhanced antibacterial activity. , 1990, FEMS microbiology letters.
[103] R. Kerbel,et al. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. , 1987, Science.
[104] R. Hodge,et al. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells , 1989, Antimicrobial Agents and Chemotherapy.
[105] M. Simpson,et al. Deoxyribonucleic acid biosynthesis in mitochondria. Purification and general properties of rat liver mitochondrial deoxyribonucleic acid polymerase. , 1970, The Journal of biological chemistry.
[106] G. Ames,et al. Bacterial periplasmic permeases belong to a family of transport proteins operating from Escherichia coli to human: Traffic ATPases. , 1990, FEMS microbiology reviews.
[107] Y. Cheng,et al. Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. , 1987, The Journal of biological chemistry.
[108] K. M. Hwang,et al. CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[109] L. Lasky,et al. Model for intracellular folding of the human immunodeficiency virus type 1 gp120 , 1989, Journal of virology.
[110] J. Payne,et al. Direct determination of the properties of peptide transport systems in Escherichia coli, using a fluorescent-labeling procedure , 1979, Journal of bacteriology.
[111] D. Norbeck,et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.
[112] S. Broder,et al. Suppression of retroviral propagation and disease by suramin in murine systems. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[113] J. C. Martin,et al. In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]-guanine and related phosphonate nucleotide analogues. , 1990, Journal of the National Cancer Institute.
[114] E. E. Tamelen. BIOORGANIC CHARACTERIZATION AND MECHANISM OF THE 2,3-OXIDOSQUALENE → LANOSTEROL CONVERSION , 1983 .